Nutrigenomix launches new genetic test for weight management

Nutrigenomix Weight Management Report

TORONTO, ON, CANADA, January 2, 2019 /EINPresswire.com/ — Nutrigenomix Inc., a global leader in genetic testing for personalized nutrition, announces the launch of a new genetic test for weight management. The new test adds to the suite of genetic tests offered by Nutrigenomix that provide actionable genetic information to help healthcare professionals and their clients determine the optimal dietary approach for achieving and maintaining a healthy body weight.

“Many of my clients have had tremendous success using the original 45-gene Nutrigenomix test that included a weight management panel,” said Kassandra Gyimesi, a Registered Dietitian Nutritionist who operates a busy weight loss clinic in Denver, Colorado. “This new genetic test for weight management will be even more appealing to my clients who have struggled to lose weight and are looking specifically for a test that focuses on weight management.”

The test includes several genetic markers that have been shown to modify a person’s response to various components of their diet, as well as genetic markers that impact eating behaviors, which can be powerful motivators that help with compliance. Dr. Ahmed El-Sohemy, Founder and Chief Science Officer of Nutrigenomix, presented the latest research on nutrigenomics and personalized nutrition at the recent American College of Nutrition Conference in Seattle where he was the recipient of the Stanley Wallach Award, which recognizes a highly esteemed investigator who has made a significant contribution to understanding the role of nutrition and human health. During his award lecture, Dr. El-Sohemy presented findings of the first randomized controlled trial of DNA-based dietary recommendations on eating behaviors by his research team at the University of Toronto. “Individuals who receive DNA-based dietary advice are much more likely to follow the recommendations they’re given,” said Dr. El-Sohemy. “This results in greater improvements to their diet, which directly impacts several indicators of health. The large Food4Me trial conducted in several European countries also showed that giving people personalized dietary advice based on genetics leads to the greatest improvements in eating behaviors.”

As one of the only nutrigenetics companies in the world supporting novel research on nutrition, genetics and health at several universities around the world, Nutrigenomix has been at the forefront of research in the field. “This new genetic test incorporates the latest scientific discoveries in the field of nutrigenomics and weight management.” said Dr. Bibiana Garcia-Bailo, Director of Research and Development. “Our team of researchers and members of our international science advisory board have used only the highest quality studies to develop this new panel. We apply the most rigorous standards for selecting every genetic marker in our panel.”

With offices in Canada, UK, Australia, Brazil and the United States, Nutrigenomix has been expanding rapidly to meet the growing demands by healthcare professionals and consumers for a high-quality genetic testing service. Being the only nutrigenetics testing company worldwide that was established at a major university, the University of Toronto, Nutrigenomix is regarded as one of the most trusted sources of genetic information for personalized nutrition. With this new test for weight management, the company will be poised to expand to weight loss clinics and has already partnered with several organizations in the health, wellness and weight loss industry.

To learn more about Nutrigenomix visit www.Nutrigenomix.com

# # #

ABOUT NUTRIGENOMIX
Nutrigenomix Inc. was founded in 2011 as a University of Toronto start-up biotechnology company that is dedicated to empowering healthcare professionals and their clients with comprehensive genomic information, with the ultimate goal of improving health and performance through precision nutrition. The company has a network of over 8,000 healthcare practitioners in 35 countries plus exclusive distributors in 10 other countries. The personalized nutrition reports are available in 8 languages and the current 45-gene test panel is available for health, sport and fertility. For more information visit Nutrigenomix.com or email info@nutrigenomix.com.

Laura Owen
Nutrigenomix Inc.
+1 800-250-4649
email us here

Nutrigenomix Wellness Video


Source: EIN Presswire

Hot Sessions You Cannot Afford to Miss at SMi’s 11th Annual European Pre-Filled Syringes Conference

Just 2 weeks remain until Europe's leading conference on Pre-Filled Syringes & Injectable Drug Devices takes place in London!

LONDON, UNITED KINGDOM, January 2, 2019 /EINPresswire.com/ —
This year’s event is focusing on the areas of the biggest growth for the market, hitting on the key hot topics in discussions and paralleling the most recent studies in the field.

Here's a run-down of the hot sessions that cannot afford to be missed:

CASE STUDY: REVIEWING CURRENT HURDLES AND THE IMPACT ON FUTURE STRATEGIES IN DEVICE DEVELOPMENT

Presentation form: Cedric Gysel, Health Care Solutions Design Manager, Johnson & Johnson Design
* Current strategies towards device development and the hindrances which arise due to current processes
* Case studies of device development which circumvent current development challenges and how that has an impact on future stages, e.g. manufacturing and distribution
* How studies conducted have led to a revision and improvement of development practices

DRUG / DEVICE PARENTERAL COMBINATION PRODUCTS: AN APPROACH TO DEFINING THE OVERALL DESIGN SPACE

Presentation form: Steve Chamberlain, Device Engineering Manager, GSK
* Understanding the interaction between the prefilled syringe and the autoinjector device
* Executing characterisation studies to build the knowledge space
* Defining a harmonised control strategy to ensure capability of Critical Quality Attributes

PRE-FILLED SYRINGES AND DRUG-DEVICE COMBINATION PRODUCTS (DDC) – A REGULATOR’S PERSPECTIVE

Presentation from: Veronika Ganeva, Biologicals Quality Assessor, MHRA
* Introduction to DDC
* The current regulatory framework in the EU
* Times of change – a look to the future
* Regulatory challenges

OPPORTUNITIES AND CHALLENGES OF IMPLEMENTATION OF PLATFORM COMPONENT FOR BIOLOGIC INJECTABLE DELIVERY

Presentation from: Elise Legendre, Head of Late stage PFS Development, Sanofi
* Why do we need a platform? A standardised approach
* Where does the platform start and stop in the development process? And are all the area impacted?
* What are the challenges for the projects? The team and the documentation?

PANEL: GLASS VS POLYMERS FOR PRIMARY PACKAGING FOR INJECTABLE DRUG DEVICES

Presentations from: James Mellman, Device Manager, Novartis, Suraj Ramachandran, Director, MSD, Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT
* The regulatory perspective surrounding primary packaging
* Technical standards
* Component integration

Check out the latest agenda, speaker line-up and attendee list on the event website:
www.pre-filled-syringes.com/ein

For those looking to attend, check out the booking options online.

— ENDS —

Contact Information:
For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 688 / Email: hsidhu@smi-online.co.uk

Sponsors of Pre-Filled Syringes & Injectable Drug Devices Europe 2019 include:
Eveon, Fruh, Harro Hoefliger, Mitsubishi Gas Chemical, Mikron, Nemera, Nelson labs, Nipro PharmaPackaging, Owen mumford, PHC Corporation, Schott, Zeon, Zwick Testing Machines

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+1 207-827-6088
email us here


Source: EIN Presswire

Author Shares An Overview of His Fiction Novel: A Profound Interview

The Girl with the Lightning Brain

Author Shares An Overview of His Fiction Novel: A Profound Interview

CHICAGO, ILLINOIS, UNITED STATES OF AMERICA, December 28, 2018 /EINPresswire.com/ — “The book would be of interest to anyone who likes science fiction or action adventure, or also socio-political thriller,” Ratza utters as he presents the book information to the readers. In a profound interview during the BookExpro America 2018, the author shares more about the first instalment of his book series.

The Girl With The Lighting Brain is a literary fiction that can be read on six different levels, wrapped in an action-adventure thriller that explains the life of the main character, Electra “Kit” Kitter, together with all the well-developed characters in the story. The book explores the challenges that the country is facing and the ways to deal with these problems. Three of six books have already been written.

The author offers a bonus, a series of games for the readers to enjoy and learn from. Everyone is invited to watch the interview through https://youtu.be/udoD-g9_LNI, take a glimpse of the authors published book and get ready for a life-changing experience!

About the Author:
Author Cliff Ratza characterizes himself a "simple scholar," having parlayed multiple degrees (math and physics, business and computer science) into a business career spanning numerous jobs, companies, and industries. He grew up in Chicago, graduating from top Illinois universities, then launched his business career. He returned to Chicago, where he teaches at several universities while continuing to work for corporations. He subsequently started a sales and marketing consulting business, and most recently added a writing career to his resume.

Cliff has written extensively throughout his career. He has published articles in four professional journals, writes copy for client Websites, and develops press releases or newsletters. He has already written three novels in his ground-breaking "Lightning Brain Series." The first, "The Girl with the Lightning Brain," is now available in print or e-book format at bookstores or online. Please visit www.authorcentrix.com or call 8885040951 for more details when you are ready to buy.

Cliff dedicates the series to readers everywhere and invites them to visit the "Lightning Brain" Website, www.lightningbrainseries.com, to learn more about the books or enter reader contests.

Product details
Paperback: 546 pages
Publisher: AuthorCentrix, Inc. (February 13, 2018)
Language: English
ISBN-10: 1641333316
ISBN-13: 978-1641333313
Product Dimensions: 6 x 1.2 x 9 inches

Book Availability:
Amazon – http://goo.gl/SABQ7R
Barnes & Noble – http://goo.gl/m5Fktp

Clifford Leonard Ratza
AuthorCentrix, Inc.
+1 888 504 0951
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Author Releases A Facebook Page for The Girl with the Lightning Brain

The Girl with the Lightning Brain

Author Releases A Facebook Page for The Girl with the Lightning Brain

CHICAGO, ILLINOIS, UNITED STATES OF AMERICA, December 28, 2018 /EINPresswire.com/ — The book entitled The Girl with the Lightning Brain authored by Clifford Ratza challenges readers to travel to the depth of their thoughts. As the extrapolation of the latest science commences, the unearthing of details from political intrigue, the rising of contemporary lifestyle – factors that give the twists in the life of Electra “Kit” Kitter. The book has undeniably reached its peak after its publication. From a self-published title, it has reached several sites and is now available for the readers.

The author has endeavored through the years to offer first-rate details about his books. Now the title reaches another milestone as it is now on social media. The readers can now be entertained through the book’s exclusive Facebook Fan Page account. Queries can now be easily raised and addressed.

Everyone is invited to visit the sites for The Girl with the Lightning Brain :

https://www.facebook.com/Cliff-Ratza-338182933350534/

amazon.com/author/cliffratza

https://twitter.com/Author_Cliff

About the Author:
Author Cliff Ratza characterizes himself a "simple scholar," having parlayed multiple degrees (math and physics, business and computer science) into a business career spanning numerous jobs, companies, and industries. He grew up in Chicago, graduating from top Illinois universities, then launched his business career. He returned to Chicago, where he teaches at several universities while continuing to work for corporations. He subsequently started a sales and marketing consulting business, and most recently added a writing career to his resume.

Cliff has written extensively throughout his career. He has published articles in four professional journals, writes copy for client Websites, and develops press releases or newsletters. He has already written three novels in his ground-breaking "Lightning Brain Series." The first, "The Girl with the Lightning Brain," is now available in print or e-book format at bookstores or online. Please visit www.authorcentrix.com or call 8885040951 for more details when you are ready to buy.

Cliff dedicates the series to readers everywhere and invites them to visit the "Lightning Brain" Website, www.lightningbrainseries.com, to learn more about the books or enter reader contests.

Product details
Paperback: 546 pages
Publisher: AuthorCentrix, Inc. (February 13, 2018)
Language: English
ISBN-10: 1641333316
ISBN-13: 978-1641333313
Product Dimensions: 6 x 1.2 x 9 inches

Book Availability:
Amazon – http://goo.gl/SABQ7R
Barnes & Noble – http://goo.gl/m5Fktp

Clifford Leonard Ratza
AuthorCentrix, Inc.
+1 888 504 0951
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Lee Bressler points out distinctions between AI and automation

Lee Bressler

Financial services industry professional Lee Bressler addresses the importance of distinguishing between artificial intelligence and process automation.

NEW YORK , NEW YORK, USA, December 28, 2018 /EINPresswire.com/ — With machine learning and AI two incredibly hot topics throughout 2018 and going into 2019, Lee Bressler looks at the key differences between groundbreaking artificial intelligence and more straightforward process automation as he debunks a number of myths surrounding the technology.

"There has been much talk about the ways in which artificial intelligence could replace current workers in the not-too-distant future," says Bressler, an equity fund portfolio manager based in New York City.

Indeed, according to researchers at the University of Oxford, a collegiate research university in Oxford, England, as many as 47 percent of jobs in the United States could be at risk of replacement by artificial intelligence, robots, and other forms of automated technology by 2040.

According to Bressler, however, the threat may not be as real or as significant as it seems. "There's something of a misconception that artificial intelligence and associated technologies will lead to huge company layoffs and massive spikes in unemployment," he explains.

"While there is little doubt,"Lee Bressler continues, "that these technologies will ultimately replace certain job roles and tasks, the panic surrounding artificial intelligence is largely unnecessary."

First and foremost, people must take into consideration the difference between artificial intelligence and more straightforward task automation, says Bressler. "There needs to be more clarity between what constitutes artificial intelligence and what simply amounts to automation," he explains, "whereby which automation employs technology solely to tackle low level, often highly repetitive tasks, which may or may not currently be handled by human workers."

Artificial intelligence, on the other hand, according to Lee Bressler, is much smarter. "Artificial intelligence works to pull together new insights, identify patterns, predict behaviors, and enhance customer experiences, among other things," he explains, "but still relies heavily on data engineers and data scientists to maintain and refine the necessary algorithms."

He continues, "While artificially intelligent solutions are capable of handling vast amounts of data more accurately and more efficiently than a human counterpart, as well as tackling many other tasks, they will always need intervention from humans."

Accordingly, Lee Bressler says that while automation will undoubtedly replace certain roles, increased efficacy of processes as a result will open up new roles, and create demand for those skilled and in a position to oversee such matters.

"Ultimately," he adds, wrapping up, "the true role of artificial intelligence right now, and in the immediate future, is to augment human capabilities and intelligence, and not simply to replace the

Chris Hinman
Web Presence, LLC
+1 757-880-3579
email us here


Source: EIN Presswire

Drawing Holds Clues to Better Long-Term Memory

After nine weeks, participants were five times more likely to remember words they had drawn than words they had written.

Drawing linked to improved retention of knowledge compared to writing

The person appears to automatically turn the act of drawing into long-term memory”

— Unnur Ottarsdottir

REYKJAVIK, ICELAND, December 28, 2018 /EINPresswire.com/ — It seems the kids who doodle and draw in their notebooks during class might be onto something.

In a study recently published in the journal ATOL: Art Therapy OnLine, 134 subjects were asked to draw the content of certain words and write other words down. Some participants recalled what they had written and drawn after three weeks, and others after nine weeks. In both cases, words that were drawn were more successfully recalled than words that were written. After three weeks, the median number was two to one in favour of drawn words. After nine weeks, that ratio grew to a staggering five to one in favour of drawing.

“The person appears to automatically turn the act of drawing into long-term memory,” says study author and art therapist Unnur Ottarsdottir. “This is the first time this type of research on such a long-term memory has been conducted worldwide prior to now, as far as we are able to tell, and the findings are very intriguing.”

Ottarsdottir began practising and researching art therapy in the early 1990s. She has published, spoken and taught at conferences and universities around the globe on the subject. Not only is drawing more effective than writing at stimulating long-term memory, says Ottarsdottir, but it is also useful for processing and working through emotions. Ottarsdottir also conducted another related research study with five children who had experienced stress or trauma and had specific learning difficulties. The children drew pictures partly to memorize coursework material, but Ottarsdottir found indications that the drawing could also relate to processing of emotions associated with difficult or traumatic experiences.

“It appears that in drawing, the children often manage to express vulnerable and complex feelings more easily than they do when speaking,” says Ottarsdottir. “Art therapy theories and methods are important in order to understand this process, and we hope that we can learn more about how art making can help us make further breakthroughs in this area in future studies.”

Ottarsdottir is available for interviews about the study and its findings by clicking on the contact information included in this release. The full paper on the experiment, “Processing Emotions and Memorising Coursework through Memory Drawing,” was published in ATOL: Art Therapy OnLine, and can be viewed at http://journals.gold.ac.uk/index.php/atol/article/view/486/pdf.

###

Unnur Ottarsdottir
Art Therapy Ottarsdottir
+354 867 0277
email us here
Visit us on social media:
Facebook

Scientist Reveals Easy Way to Improve Memory 500%


Source: EIN Presswire

Device On The Market Reduces Dental Pain: New Research

Visit the dentist without pain, with Buzzy!

We're starting to understand the link between oral and overall health. Visiting the dentist is key to good health. This new study shows Buzzy may help patients who fear going to the dentist.”

— Amy Baxter MD, CEO & Chief Medical Officer, Pain Care Labs

ATLANTA, GEORGIA, US, December 27, 2018 /EINPresswire.com/ — News Alert: Between 9% and 15% of Americans say they avoid going to the dentist, according to the Cleveland Clinic. The needle pain and fear behind good oral health are often rooted in a negative childhood experience in the dentist's chair. New research about a device created by the industry leader in local pain relief may change that.

A new study out this month demonstrates a fast, inexpensive device that is widely used for intramuscular injections in hospitals and homes may conquer those early negative experiences. Buzzy, manufactured by Pain Care Labs, is a vibrating ice pack used in over 5,000 hospitals and clinics to physically block needle pain. Last year, the company won the prestigious Frost & Sullivan "Local Pain Relief" technology leader award. In large independent studies, Buzzy has been proven equivalent to both the leading topical anesthetic and virtual reality.

The study randomized sixty (60) children, aged seven (7) years old, who needed an injection on both sides of the mouth. One side got standard care, while the other side used Buzzy's cold and vibration in addition to the control protocol. Heart rate, the dentists' rating of pain on a movement scale, and the kids themselves all demonstrated significantly lower pain on the side of the mouth with Buzzy.

"Cold and vibration are potent pain relievers for adults," noted Pain Care Labs' CEO Amy Baxter MD. "This study is important because it shows that even for the hardest patient group–kids injected in a dentist's chair–Buzzy's cold and vibration works for needle pain."

Patients in the Buzzy group did significantly better in all domains: reduced discomfort; lower heart rate; lower pain score. The authors observed Buzzy to be effective in reducing discomfort and fear in children undergoing infiltration dental analgesia.

"Our Buzzy device is FDA-cleared to control pain associated with injections," says Dr. Amy Baxter. "We know dentists also use our technology to address fear. We are hopeful that studies like this one will persuade other dental professionals to add our simple, affordable, reusable device to their existing menu of pain relief options."

About Pain Care Labs

Founded in 2006 by pediatric emergency doctor and pain researcher Amy Baxter MD FAAP FACEP, Pain Care Labs is on a mission to eliminate unnecessary pain. Using the physiologic technique of “gate control”, the devices block pain by stimulating the motion nerves (like TENS units) and cold nerve feedback system. Instead of electric shocks, Pain Care Labs determined the frequency that naturally stimulates the motion nerves with comfortable vibration. Unique intense ice packs reduce inflammation and add a powerful inhibitory pain relief called Descending Noxious Inhibitory Control. The company’s award-winning first device, Buzzy for Shots, created a new category of pain reliever. In 2017 the company was awarded the “Industry Leader in Local Pain Relief” from Frost & Sullivan. Buzzy is used worldwide and has blocked pain from over 31 million needles. VibraCool is used for athletic and post-operative pain. New DuoTherm Vibrating Back Pain reliever will be introduced at CES this January. See other projects and company information at http://www.paincarelabs.com.

Jennifer Tipping
Pain Care Labs
+1 877-805-2899
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Buzzy at the dentist, Brazil


Source: EIN Presswire

eQuine Holdings discloses 8% stake in AngioSoma (SOAN)

eQuine Holdings has filed a form 13D with the SEC disclosing an 8% stake in AngioSoma (SOAN), after announcing its LOI for the acquisition of Diabetes Relief

AngioSoma (OTCBB:SOAN)

DALLAS, TEXAS, USA, December 27, 2018 /EINPresswire.com/ — eQuine Holdings, a Class II Multi-Family Office, has disclosed an eight percent (8%) equity stake in AngioSoma (SOAN)

On December 17, 2018 AngioSoma announced a Partially Binding Letter of Intent to acquire Diabetes Relief.

A copy of SEC form 13D can be found at: https://www.sec.gov/Archives/edgar/data/1502152/000091228218000168/angiosoma-atwood13d_122618.htm

About eQuine Holdings, LLC – eQuine Holdings, LLC is a Class II multi-family office, responsible for managing the day to day operations of various interests in private and public companies. For the past decade, ultra-high net worth families have entrusted eQuine to advise them on wealth preservation & growth, tax advisement, risk mitigation and legacy generational planning.

About AngioSoma (SOAN) – AngioSoma is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to pharmaceutical or endovascular interventions. Our “end to end” solution will provide interventional radiologists, cardiologists, and internal medicine physicians with both pharmaceutical and or endovascular interventional options prior to infarction or critical limb ischemic events, stabilizing or reversing the atherosclerotic disease. For pharmaceutical stabilization, our Liprostin™ product for treatment of peripheral artery disease (“PAD”) completed preliminary U.S. Food and Drug Administration (“FDA”) required Phase I and Phase II clinical trials successfully and is entering Phase III prior to approval. For long term preventative measures, our Transdermal PGE-1 Patch will provide ongoing treatment for chronic cardiovascular disease by delivery of PGE-1 or Liprostin™ through the skin.In all, we have a robust product pipeline from 20+ years of research and development, with existing patents, provisional patents, formulations, and trademarks from previously successful products

About Diabetes Relief – Diabetes Relief licenses medical facilities for the treatment of metabolic disorder, specializing in diabetes, for the use of patented protocols, processes, and intellectual property. Treatments are individualized to a patient’s condition and metabolic state. Diabetes Relief, through providing thousands of treatments, has seen vast improvements for patients. Clinical trials for FDA approval of Liprostin™, that is intended to treat Peripheral Artery Disease, or PAD, may be facilitated by the acquisition.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those indicated in such statements, including the risks described in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect changed assumptions, the occurrence of anticipated or unanticipated events, new information or changes to future results over time or otherwise.

Media Relations
eQuine Holdings, LLC
+1 907-738-8458
email us here
Visit us on social media:
Facebook
LinkedIn


Source: EIN Presswire

BLOCKCHAIN INTEGRATION INTO BIG BUSINESS: HOW IT WORKS

NY, NEW YORK, UNITED STATES, December 27, 2018 /EINPresswire.com/ — Blockchain technology has come into our modern life quickly and confidently. The data hashing technology in private networks is made as the mechanism providing the record and encryption of any transaction between two bodies in a permanent and provable way. Truth, but as long as companies, entrepreneurs and investors are afraid of new technologies like blockchain or cryptocurrency and do not follow the technological trends, the digital economy will not reach its top.

Anyway, blockchain always develops and finds its admirers. The mayor of the largest metropolis of South Korea has announced about his intention to make Seoul a “smart” city based on the blockchain technology. The strategy called Blockchain Urban Plan (2018-2022) involves 14 public services of 5 industries, for instance, human services, transport, certificate issuing, voting system, and donations management.
According to the opinions of the banking sector representatives, the banks sharply react to the technologies as the new market is not regulated. That is why the banks are not ready to integrate the cryptographic economy into the banking sector because the main features of blockchain such as anonymity and decentralization are at variance with the initial idea of the bank.

In spite of it, the blockchain payment service CLA group conducted the press release (November 28, 2018) where one of the largest investment banks Goldman Sachs and multinational investment banking enterprise Morgan Stanley were announced to be among the users of this blockchain-based service.

Apart from that, the holding company JPMorgan, the financial corporation Citigroup and financial services company Barclays become the members of CLA Group. The financial institution of the foreign exchange market (FX) reaches $5 trillion daily and is meant to be the first FX settlement service running on the base of the blockchain technology.
The intention to accept blockchain in the main financial mechanism of both companies will lead to improvement of payment netting process. The reduced costs, the increase of operation efficiency, the business growth and so on will gain their support throughout the blockchain technology usage. There is nothing strange that these investment giants such as Goldman Sachs and Morgan Stanley are going to launch the products related to Bitcoin.
In addition to Goldman Sachs and Morgan Stanley news, the blockchain technology has not gone past the largest online retailer in the world – Amazon. On the base of blockchain, this tech giant launches a service in order to provide the clients with easy development of their blockchain networks with no difficulties and costs during the creation of their own platform.
Recently created the Amazon Managed Blockchain is known to be a service providing reliable, manageable, and scalable blockchain networks. The Amazon users are able to build the platform using the open source frameworks – either Ethereum or Hyperledger Fabric.

The Amazon Managed Blockchain is another style of online trading and web services. The platform powers a lot of websites and media providers such as Netflix platform. What is more, the Amazon Quantum Ledger Database, which was created as the applications’ data guard, works as a ledger database meeting the demands of many users. The organizations use QLDB for recording and analyzing the history of economic and financial activity. With QLDB, data can be neither altered nor deleted. As a result, the history of the applications’ data is saved and owned by the central trusted authority. The people who are interested in this service are able to sign up and create a blockchain network if they are approved.

Despite the fact that the cryptocurrency sector which is known to be the most popular area for the blockchain technology usage experiences hard times, blockchain remains to be widespread and popular around the world. With its help, it will be more than possible to automate most of the business processes which are necessary for business activity. Then, in the view of the analytical and research company COR Index INC (New York, US) that professionally deals with studying of data and information about blockchain projects and cryptocurrency at all, large business companies that are leaders in their industries cannot ignore and deny the modern technologies such as blockchain. 2018 has shown that the use of blockchain technology became a necessity. For some many industries, blockchain is meant to be a priority goal for its integration into their business processes.

Artem Baykov
COR Index inc
+1 9292165387
email us here
Visit us on social media:
Twitter


Source: EIN Presswire

Vein911® Vein Treatment Centers Medical Director Elected Fellow of the American College of Radiology

Vein911® Vein Treatment Centers announced that Medical Director and CEO,Christopher Pittman,M.D.,has been elected a Fellow of the American College of Radiology

I am humbled, honored and excited to be nominated and elected a Fellow of the American College of Radiology”

— Dr. Chris Pittman, CEO of Vein911® Vein Treatment Centers

TAMPA, FL, UNITED STATES, December 27, 2018 /EINPresswire.com/ — Vein911® Vein Treatment Centers announced today that Medical Director and CEO, Christopher Pittman, M.D., DABR, FACPh has been elected a Fellow of the American College of Radiology (ACR) — one of the highest honors the ACR can bestow on a member. Fellowship symbolizes exceptional achievement in the fields of diagnostic radiology, interventional radiology, nuclear medicine, radiation oncology, and/or medical physics. ACR Fellows have distinguished themselves through one or more domains: service to the ACR and/or organized radiology/medicine; outstanding teaching of radiology; and/or significant scientific or clinical research in radiology and/or significant contributions to the literature. Only 10 percent of College members have been awarded this honor. Following a convocation ceremony to be held May 19, 2019 at the ACR Annual Meeting, newly elected Fellows may place FACR after their name to acknowledge the accomplishment.

Christopher Pittman, M.D., DABR, FACPh is a nationally recognized expert and thought leader on health care policy and politics, medical economics, and health information technology. He is Medical Director and CEO of Vein911® Vein Treatment Centers and Managing Director of Health Performance Specialists. Dr. Pittman serves on the Board of Directors of the American College of Phlebology (ACPh) and is the ACPh Delegate to the American Medical Association. He previously served on the Executive Committee of the ACPh Foundation, the Board of Governors of the Florida Medical Association, and is Past President of the Florida Medical Association Political Action Committee (FMA PAC) and Past President of the Hillsborough County Medical Association.

Dr. Pittman was recently elected a Fellow of the American College of Phlebology. Fellows of the American College of Phlebology (FACPh) are recognized for their substantial commitment and contribution to the specialty of venous disease treatment and care; shown through volunteerism, authored publications, education, years of practice, leadership and other qualifications that lead to the advancement of vein care.

“I am humbled, honored and excited to be nominated and elected a Fellow of the American College of Radiology,” said Dr. Chris Pittman, Medical Director and CEO of Vein911® Vein Treatment Centers.

About Vein911® Vein Treatment Centers
Vein911® is a leading provider of both medical and cosmetic vein care including varicose veins, ankle swelling, restless legs, night cramps, venous leg ulcers, and cosmetically disturbing veins of the hands, face and legs. Our world-class vein treatment centers offer state of the art technology within elegant and comfortable surroundings and a family atmosphere. Our non-surgical medical procedures include VenaCure EVLT Endovenous Laser Treatment, Venefit procedure using ClosureFast Endovenous Radiofrequency Ablation (RFA) and Ultrasound-Guided Foam Sclerotherapy which is the future of vein care available today at Vein911®. Our cosmetic procedures include Visual Sclerotherapy, the gold standard treatment for spider veins, and VeinGogh, an immediately effective treatment for facial veins. Vein911® is the varicose vein and spider vein treatment center of choice for physicians and their patients who are experiencing vein disease. Our vein treatment centers are conveniently located throughout the Tampa Bay area and are led by board-certified vein care specialist physicians.

Douglass Pace
Vein911 Vein Treatment Centers
+1 855-834-6911
email us here


Source: EIN Presswire